Shown to Support ‘Good’ Cholesterol (HDL), Slo-NiacinÂ® Dietary Supplement Features a Unique, Patented PolygelÂ® System to Deliver Controlled-Release Niacin
MAPLE GROVE, Minn., July 14 /PRNewswire/ — People who are whole-heartedly searching for a dietary supplement to support heart health can turn to Slo-NiacinÃ‚®. Trusted by healthcare professionals for more than 20 years, Slo-NiacinÃ‚® is a niacin supplement that has been shown in clinical studies to boost “good” cholesterol (HDL).
“Slo-NiacinÃ‚® features a unique patented polygelÃ‚® system that gradually delivers niacin to the body,” said Dr. Robert Knopp, professor of medicine at Harborview Medical Center and director of the Northwest Lipid Research Clinic, Seattle, WA. “I have been recommending Slo-NiacinÃ‚® to my patients for two decades because its innovative formulation sets it apart from all other dietary supplement niacin products.”
Slo-NiacinÃ‚® Tablets utilize a patented polygelÃ‚® controlled-release delivery system not available in other dietary supplement niacin products. This technology ensures the gradual and sustained release of niacin in the body and is designed to reduce the incidence of flushing commonly associated with immediate-release niacin use.
“It is important to recognize that Slo-NiacinÃ‚® is a controlled-release niacin and not an immediate-release or flush-free niacin,” added Dr. Knopp. “Immediate-release niacin requires niacin to be taken several times a day, and side effects such as flushing can be a problem. Flush-free niacins may not cause flushing, but they have not been shown to have any significant effect on cholesterol.”
Niacin is a type of B vitamin that occurs naturally and aids in the function of the digestive system, skin and nerves. Niacin is sometimes referred to as nicotinic acid and has been used to help manage cholesterol since the 1950s. When used under the care and monitoring of a healthcare provider, niacin is the most effective agent available for increasing HDL. Slo-NiacinÃ‚® is effective alone or as a complement to statins.
About Slo-NiacinÃ‚® Tablets
Slo-NiacinÃ‚® is economical and often costs less than an insurance co-payment, at approximately $16 per month for one hundred 500 mg tablets. Three dosage strengths of Slo-NiacinÃ‚® Tablets are available to help meet a person’s individual goals (250 mg, 500 mg, and 750 mg). However, taking more than 500 mg of niacin daily should be done only under the advice and monitoring of your healthcare professional. Slo-NiacinÃ‚® Tablets are manufactured by Upsher-Smith Laboratories, Inc., a trusted manufacturer of high quality prescription and dietary supplement products, and are conveniently available at pharmacies and other retailers nationwide. In the 20 years that Upsher-Smith has been manufacturing Slo-NiacinÃ‚®, more than 10 million bottles have been sold. For more information, visit www.slo-niacin.com for coupons and a store locator.
About Upsher-Smith Laboratories, Inc.
Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit www.upsher-smith.com.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Important Safety Information
Read the information leaflet provided with each bottle of Slo-NiacinÃ‚® Tablets. Do not use Slo-NiacinÃ‚® Tablets if you have a known sensitivity or allergy to niacin. Do not take niacin unless under your healthcare provider’s supervision if you have heart disease (particularly, recurrent chest pain or recent heart attack), gallbladder disease, gout, arterial bleeding, glaucoma, diabetes, impaired liver function, stomach ulcers, or are pregnant or lactating. Before taking more than 500 mg/day, call your healthcare provider. If you are taking high blood pressure or cholesterol-lowering drugs, call your healthcare provider before taking niacin due to possible interactions. Case reports of unexplained muscle-related complaints, including discomfort, weakness, or tenderness, have been documented with HMG-CoA Reductase Inhibitors in combination with niacin. Increased uric acid, glucose, and abnormal liver function tests have been reported in persons taking 500 mg/day or more. Discontinue use and call your healthcare provider immediately if you experience persistent flu-like symptoms (nausea, vomiting, not feeling well), loss of appetite, decreased and dark-colored urine, muscle discomfort or weakness, irregular heartbeat or vision problems. Niacin may cause temporary flushing, itching and tingling, feelings of warmth and headache, particularly when beginning, increasing dosage or changing brands. This safety information is not all-inclusive. For more information, contact your healthcare provider, call 1-800-654-2299, or visit www.slo-niacin.com.
Mayo Clinic. http://www.mayoclinic.com/health/niacin/cl00036. April 13, 2009.
MedlinePlus. Niacin. http://www.nlm.nih.gov/medlineplus/ency/article/002409.htm. Accessed December 17, 2009.
American Heart Association. http://www.americanheart.org/presenter.jhtml?identifier=180. January 13, 2010.
Harvard Health Letter. “Niacin into the void: Failure of HDL cholesterol drug may be this B vitamin’s big chance.” April 2007.
Lavie CJ, Mailander L, Milani. “Marked benefit with sustained-release niacin therapy in patients with ‘isolated’ very low levels of high-density lipoprotein cholesterol and coronary artery disease.” Am J Cardiol. 1992;69:1083-1085.
Squires RW, Allison TG, Gau GT, et al. “Low-Dose, Time-Release Nicotinic Acid: Effects in Selected Patients With Low Concentrations of High-Density Lipoprotein Cholesterol.” Mayo Clin Proc. 67:855-860, 1992.
Gray DR, Morgan T, Chretien SD, Kashyap ML. “Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans.” Ann Intern Med. 1994;121:252-258.
Knopp RF, Retzlaff BM, Fish B et al. “The SLIM study: Slo-NiacinÃ‚® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia.” Journal of Clinical Lipidology, Volume 3, Issue 3, Pages 167-178.
Slo-Niacin product information. http://www.slo-niacin.com/about-slo-niacin/directions-for-use. Upsher-Smith Laboratories, 2010.
Drugstore.com website. http://www.drugstore.com. February 11, 2010.
SOURCE Upsher-Smith Laboratories, Inc.